NASDAQ:IPHA - Nasdaq - US45781K2042 - ADR - Currency: USD
Overall IPHA gets a fundamental rating of 2 out of 10. We evaluated IPHA against 558 industry peers in the Biotechnology industry. IPHA may be in some trouble as it scores bad on both profitability and health. IPHA is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -44.54% | ||
ROE | -560.01% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 8.02 | ||
Debt/FCF | N/A | ||
Altman-Z | -4.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.6 | ||
Quick Ratio | 2.6 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 24.08 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.15
+0.01 (+0.47%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 24.08 | ||
P/S | 13.79 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 19.7 | ||
P/tB | 19.7 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -44.54% | ||
ROE | -560.01% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 8.02 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 19.61% | ||
Cap/Sales | 3.1% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.6 | ||
Quick Ratio | 2.6 | ||
Altman-Z | -4.7 |